However, our subgroup analyses showed that the association between increased circulating galectin-3 and higher all-cause mortality in AS patients after TAVR remained significant in studies with adjustment of eGFR, indicating that the association between galectin-3 and prognosis after TAVR is unlikely to be mediated by kidney dysfunction. The gene discussed is LGALS3; the disease is aortic stenosis.